New drug cocktail aims to save bladders in cancer fight

NCT ID NCT06809140

Recruiting now Disease control Sponsor: Matthew Galsky Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 06, 2026 · Updated 5 times

Summary

This phase 2 trial tests two drugs, enfortumab vedotin and pembrolizumab, in 47 people with muscle-invasive bladder cancer. The goal is to see if the combination can eliminate the cancer so patients can keep their bladder instead of having it surgically removed. After three cycles of treatment, doctors check if the cancer is gone; if so, patients continue on maintenance therapy. If not, they proceed to standard bladder removal surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin and pembrolizumab
What this could lead to: If successful, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, preserving quality of life.
What could go wrong: This is a small, early-phase trial (47 people) with no guarantee of success. Some patients may still need bladder removal if the cancer does not fully respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA

Contacts and locations

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.